Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-Ib Study in Male Patients With Stable Allergic Asthma With Airway Hyperresponsiveness to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation - A Randomised, Double-blind, Placebo-controlled, Parallel-group (Per Dose Level) Dose-escalation Study in Asthmatic Patients

NCT01577953 is registered in ClinicalTrials.gov with Sterna Biologicals GmbH & Co. KG as lead sponsor.

NCT NCT01577953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01577953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-Ib Study in Male Patients With Stable Allergic Asthma With Airway Hyperresponsiveness to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Inhaled Single Doses of SB010, a Human GATA-3-specific DNAzyme Solution for Nebulisation - A Randomised, Double-blind, Placebo-controlled, Parallel-group (Per Dose Level) Dose-escalation Study in Asthmatic Patients
Lead sponsor
Sterna Biologicals GmbH & Co. KG
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
August 31, 2012
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma